GSK2894631A, identified by its CAS number 2101626-26-8, is a chemical compound that has been investigated primarily in the context of pharmaceutical research. It is known to be a selective inhibitor of certain enzymes, which positions it as a potential therapeutic agent in treating various diseases, particularly those related to inflammation and immune responses. The compound's structure typically includes functional groups that enhance its binding affinity and specificity for its target enzymes. In preclinical studies, GSK2894631A has demonstrated promising efficacy and safety profiles, making it a candidate for further development in clinical trials. Its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), are crucial for determining its suitability for therapeutic use. As with many investigational drugs, ongoing research aims to elucidate its mechanism of action, optimize its formulation, and assess its long-term effects in biological systems.

GSK2894631A

2101626-26-8: GSK2894631A, identified by its CAS number 2101626-26-8, is a chemical compound that has been investigated primarily in the context of pharmaceutical research. It is known to be a selective inhibitor of certain enzymes, which positions it as a potential therapeutic agent in treating various diseases, particularly those related to inflammation and immune responses. The compound's structure typically includes functional groups that enhance its binding affinity and specificity for its target enzymes. In preclinical studies, GSK2894631A has demonstrated promising efficacy and safety profiles, making it a candidate for further development in clinical trials. Its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), are crucial for determining its suitability for therapeutic use. As with many investigational drugs, ongoing research aims to elucidate its mechanism of action, optimize its formulation, and assess its long-term effects in biological systems.

7-(Difluoromethoxy)-N-(trans-4-(2-hydroxypropan-2-yl)cyclohexyl)quinoline-3-carboxamide

HPGDS inhibitor 2

<p>HPGDS inhibitor 2 (GSK-2894631A) is a potent, selective hematopoietic prostaglandin D synthase (h-pgds) inhibitor, IC50 = 9.9 nm.</p>

CAS 2101626-26-8

GSK2894631A

7-(Difluoromethoxy)-N-(trans-4-(2-hydroxypropan-2-yl)cyclohexyl)quinoline-3-carboxamide

Ref: IN-DA01KDXU

HPGDS inhibitor 2

Ref: 54-BUP08497

HPGDS inhibitor 2

Ref: TM-T7948